Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D'Alo', Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio Pinto
Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review
Fingerprint
Entra nei temi di ricerca di 'Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab'. Insieme formano una fingerprint unica.